Chapter 6 Mouse Models to Investigate Anti-Cancer Effects of VEGF Inhibitors

Methods in Enzymology

Volumn 445, Issue , 2008, Pages 125-139

  Crawford, Yongping ^a   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CEDIRANIB; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A461; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY G 6 31; MONOCLONAL ANTIBODY MF 1; MONOCLONAL ANTIBODY Y 0317; PACLITAXEL; SEMAXANIB; SORAFENIB; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BENIGN TUMOR; BLOOD VESSEL; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENDOCRINE TUMOR; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENETIC MODEL; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHYSIS TUMOR; INHIBITION KINETICS; INTESTINE CARCINOMA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RETINA MACULA DEGENERATION; REVIEW; RHABDOMYOSARCOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, MUTANT STRAINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56049117652     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(08)03006-1     Document Type: Review

References (79)

1. Adamis A.P., Shima D.T., Tolentino M.J., Gragoudas E.S., Ferrara N., Folkman J., D'Amore P.A., and Miller J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol 114 (1996) 66-71
2. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., and Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92 (1995) 10457-10461
3. Algire G.H., Chalkley H.W., Legallais F.Y., and Park H.D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice. to wounds and to normal and neoplastic trasplants. J. Natl. Cancer Inst. 6 (1945) 73-85
4. Amos-Landgraf J.M., Kwong L.N., Kendziorski C.M., Reichelderfer M., Torrealba J., Weichert J., Haag J.D., Chen K.S., Waller J.L., Gould M.N., and Dove W.F. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc. Natl. Acad. Sci. USA 104 (2007) 4036-4041
5. Ansiaux R., Baudelet C., Jordan B.F., Crokart N., Martinive P., DeWever J., Gregoire V., Feron O., and Gallez B. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res. 66 (2006) 9698-9704
6. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of Angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
7. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 6 (2000) 737-744
8. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
9. Campa C., Kasman I., Ye W., Lee W., Fuh G., and Ferrara N. Effects of an anti-VEGF monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest. Ophthalmol. Vis. Sci. 49 (2008) 1178-1183
10. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
11. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declereq C., Pawling J., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
12. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
13. Christofori G., Naik P., and Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol 9 (1995) 1760-1770
14. Crabtree J.S., Scacheri P.C., Ward J.M., Garrett-Beal L., Emmert-Buck M.R., Edgemon K.A., Lorang D., Libutti S.K., Chandrasekharappa S.C., Marx S.J., Speigel A.M., and Collins F.S. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. USA 98 (2001) 1118-1123
15. Dickson P.V., Hamner J.B., Sims T.L., Fraga C.H., Ng C.Y., Rajasekeran S., Hagedorn N.L., McCarville M.B., Stewart C.F., and Davidoff A.M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13 (2007) 3942-3950
16. Dings R.P., Loren M., Heun H., McNiel E., Griffioen A.W., Mayo K.H., and Griffin R.J. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13 (2007) 3395-3402
17. Dong J., Grunstein J., Tejada M., Peale F., Frantz G., Liang W.C., Bai W., Yu L., Kowalski J., Liang X., Fuh G., Gerber H.P., and Ferrara N. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23 (2004) 2800-2810
18. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
19. Faivre S., Demetri G., Sargent W., and Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6 (2007) 734-745
20. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2 (2002) 795-803
21. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
22. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
23. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004) 391-400
24. Ferrara N., Mass R.D., Campa C., and Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58 (2007) 491-504
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
26. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
27. Fox W.D., Higgins B., Maiese K.M., Drobnjak M., Cordon-Cardo C., Scher H.I., and Agus D.B. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8 (2002) 3226-3231
28. Fujita K., Sano D., Kimura M., Yamashita Y., Kawakami M., Ishiguro Y., Nishimura G., Matsuda H., and Tsukuda M. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol. Rep. 18 (2007) 47-51
29. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65 (2005) 671-680
30. Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., and Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60 (2000) 6253-6258
31. Gerber H.P., Wu X., Yu L., Wiesmann C., Liang X.H., Lee C.V., Fuh G., Olsson C., Damico L., Xie D., Meng Y.G., Gutierrez J., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 104 (2007) 3478-3483
32. Goodlad R.A., Ryan A.J., Wedge S.R., Pyrah I.T., Alferez D., Poulsom R., Smith N.R., Mandir N., Watkins A.J., and Wilkinson R.W. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 27 (2006) 2133-2139
33. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., Seetharam S., Koons A., Hari D.M., Kufe D.W., and Weichselbaum R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
34. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
35. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267 (1992) 26031-26037
36. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., and Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161 (2002) 1917-1924
37. Hung H. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Mol. Cancer Ther. 6 (2007) 2149-2157
38. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
39. Ilyas M., Straub J., Tomlinson I.P., and Bodmer W.F. Genetic pathways in colorectal and other cancers. Eur. J. Cancer 35 (1999) 1986-2002
40. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 (2002) 193-202
41. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
42. Kerbel R.S. Antiangiogenic therapy: A universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
43. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., and Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271 (1996) 7788-7795
44. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
45. Kiselyov A., Balakin K.V., and Tkachenko S.E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Invest. Drugs 16 (2007) 83-107
46. Korsisaari N., Kasman I.M., Forrest W.F., Pal N., Bai W., Fuh G., Peale F.V., Smits R., and Ferrara N. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc. Natl. Acad. Sci. USA 104 (2007) 10625-10630
47. Korsisaari N., Ross J., Wu X., Kowanetz M., Pal N., Hall L., Eastham-Anderson J., Forrest W.F., Van Bruggen N., Peale F.V., and Ferrara N. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin. Cancer Res. 14 (2008) 249-258
48. Kowanetz M., and Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 12 (2006) 5018-5022
49. Lakhani V.T., You Y.N., and Wells S.A. The multiple endocrine neoplasia syndromes. Annu. Rev. Med. 58 (2007) 253-265
50. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169 (2005) 681-691
51. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., and Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281 (2006) 951-961
52. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., and Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676
53. Moser A.R., Pitot H.C., and Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
54. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., and de Vos A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6 (1998) 1153-1167
55. Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C., and de Vos A.M. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. USA 94 (1997) 7192-7197
56. Ng E.W., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
57. Piecha G., Chudek J., and Wiecek A. Multiple endocrine neoplasia type 1. Eur. J. Intern. Med. 19 (2008) 99-103
58. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007) 45-51
59. Poon R.T., Fan S.T., and Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19 (2001) 1207-1225
60. Preston S., Leedham S., Oukrif D., Deheregoda M., Goodlad R., Poulsom R., Alison M., Wright N., and Novelli M. The development of duodenal microadenomas in FAP patients: The human correlate of the Min mouse. J. Pathol. 214 (2008) 294-301
61. Red-Horse K., Crawford Y., Shojaei F., and Ferrara N. Endothelium-microenvironment interactions in the developing embryo and in the adult. Dev. Cell 12 (2007) 181-194
62. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
63. Rowe D.H., Huang J., Kayton M.L., Thompson R., Troxel A., O'Toole K.M., Yamashiro D., Stolar C.J., and Kandel J.J. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J. Pediatr. Surg. 35 (2000) 30-32 discussion 32-33
64. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., and Shuman M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
65. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., and Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell Physiol. 195 (2003) 241-248
66. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., and Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006) 2542-2550
67. Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., and Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97 (2001) 785-791
68. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39 (2006) 469-478
69. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312 (2006) 549-560
70. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol 25 (2007) 911-920
71. Soffer S.Z., Moore J.T., Kim E., Huang J., Yokoi A., Manley C., O'Toole K., Stolar C., Middlesworth W., Yamashiro D.J., and Kandel J.J. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg. 36 (2001) 1177-1181
72. Su L.K., Kinzler K.W., Vogelstein B., Preisinger A.C., Moser A.R., Luongo C., Gould K.A., and Dove W.F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256 (1992) 668-670
73. Tejada M.L., Yu L., Dong J., Jung K., Meng G., Peale F.V., Frantz G.D., Hall L., Liang X., Gerber H.P., and Ferrara N. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin. Cancer Res. 12 (2006) 2676-2688
74. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
75. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
76. Yang Y., and Hua X. In search of tumor suppressing functions of menin. Mol. Cell Endocrinol. 265-266 (2007) 34-41
77. Yao J.C. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 21 (2007) 163-172
78. Yu L., Wu X., Cheng Z., Lee C.V., Lecouter J., Campa C., Fuh G., Lowman H., and Ferrara N. Interaction between Bevacizumab and Murine VEGF-A: A Reassessment. Invest. Ophthalmol. Vis. Sci. 49 (2008) 522-527
79. Zhang J., Jia Z., Li Q., Wang L., Rashid A., Zhu Z., Evans D.B., Vauthey J.N., Xie K., and Yao J.C. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 (2007) 1478-1486